---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-25-000010"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:42:36.378480+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lisata Therapeutics reports 2024 net loss $20M, cash $31.2M; promising Phase 2b pancreatic cancer data

## Summary
- Revenue $1.0M from Kuva license (vs $0 in 2023); operating expenses down 8.9% to $23.4M.
- Net loss $20.0M vs $20.8M in 2023; cash, equivalents & securities $31.2M; runway into Q2 2026.
- Phase 2b ASCEND (mPDAC) showed positive OS trend; four complete responses in certepetide arm, none in placebo.
- BOLSTER (cholangiocarcinoma) first-line enrollment complete; topline data expected mid-2025.
- iLSTA (PDAC+immunotherapy) 27 of 30 enrolled; enrollment completion H1 2025.

## SEC filing metadata
- accession: 0000320017-25-000010
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001725000010/0000320017-25-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001725000010/clbs-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-25-000010
- JSON: https://secwatch.observer/filing/0000320017-25-000010.json
- Plain text: https://secwatch.observer/filing/0000320017-25-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.